Large multi-center Phase 3 human clinical trials testing efficacy, absolute risk reduction, and adverse-event rates against placebo or active gold-standard comparators. Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Tenofovir disoproxil fumarate, when given in combination with emtricitabine as pre-exposure prophylaxis during pregnancy and lactation, appears not to have an effect on creatinine clearance and the frequency of adverse kidney...
Gantenerumab treatment was associated with greater parenchymal volume reduction than placebo, with no difference between ARIA and non-ARIA groups.
Higher anifrolumab exposure and reduced UPCR24 were each associated with decreased risk of treatment discontinuation.
In this exploratory analysis of reconstructed individual patient data, perioperative durvalumab was associated with an estimated +19 pp higher cure fraction (95% CI: +10 to +29); cure regression assigned an Akaike weight of...
Patient-important thrombotic events were few, limiting precision for stroke and VTE estimates.
Nortriptyline was not more effective than placebo in reducing FD symptoms in participants pre-selected based on CYP2D6 genotype, although a biological effect of nortriptyline could not be ruled out.
Switching from Ref-GLM to BAT2506 showed comparable efficacy, safety, immunogenicity, and PK profiles to continued treatment with BAT2506 or Ref-GLM.
Four-week time-to-positivity phase 2a data provided more information compared to the 2-week time-to-positivity data for the prediction of culture conversion.
FDG-PET-guided adaptive dose-redistributed radiotherapy resulted in similar acute and long-term toxicity, tumor control and survival as cRT..
Joint profiles were differentially associated with NfL (P = 0.0427) and brain-PAD (P = 0.0296).
These findings support mRNA-1083 as a single-dose approach to seasonal vaccination against influenza and SARS-CoV-2 in adults ≥50 years.
Sinovac serum-free rabies vaccine induced rapid, robust, and persistent immune responses under both 5-dose and simplified 4-dose schedules, with a favorable safety profile.
Contributing to the limited data on dissemination in resource-limited settings, our findings provide context-informed recommendations that can be applied to similar settings.
Three of the four participants had undergone SOT.
In children aged 6 to <12 years with mild-to-moderate COVID-19 treated with ensitrelvir, we observed a favorable safety profile, adult-matched plasma concentration-time profile, and a greater reduction in viral RNA vs placebo.
CD8+ T-cell phenotype, tumor reactivity, and in vivo persistence emerged as strong predictors of clinical outcome.
In patients undergoing elective PCI, the risk of periprocedural ischemic events is adequately captured by the total stent length.
After RNI, the 3-year incidence of clinical hypothyroidism was 13%, with no statistically significant difference between proton and photon modalities.
Mepolizumab improves outcomes in patients with CRSwNP with one or multiple prior surgeries; however, may offer greater benefit when initiated after a single surgery.
Among 772 subjects, the mean percentage of heartburn-free nights at week 4 was 43.3% for placebo vs 59.9% for vonoprazan 10 mg (least squares [LS] mean difference = 16.5%, P < 0.0001) and 56.4% for vonoprazan 20 mg (LS mean...
CZP plasma concentrations were influenced by both dose and dose adjustment in a predictable manner, with median plasma levels twice as high in the 400-mg group than in the 200-mg group, with a 2-fold increase after the dose...
Luspatercept offers rapid and durable benefits by improving anemia-related symptoms and quality of life in patients with NTDT.
Picankibart provided effective skin clearance in Chinese participants by week 16.
Similar effects of belimumab on biomarker outcomes were observed within the induction groups.
Our results show the estimated MID for short-term NT-proBNP improvement in PAH and PH-ILD is remarkably similar at 48%.
Baseline 18F-FDG PET-derived metabolic and radiomic parameters do not provide meaningful incremental prognostic value beyond tumour burden and clinical factors.
Three external reference anchors were used to assess known-groups validity, based on clinician and study partner ratings of disease severity over time.
This comprehensive analysis is the first report characterizing the immunogenicity profile of ligelizumab.
Atropine sulphate ophthalmic solution (0.01%) exhibited negligible rebound in myopia progression after treatment cessation following 3 years of.
In this post hoc analysis of SURMOUNT-5, a greater proportion of tirzepatide-treated participants in both responder groups achieved all body weight reduction thresholds versus semaglutide.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
